An Observational Study of Octreotide Subcutaneous Depot in Patients With Acromegaly

Long-term Safety and Efficacy Study of Octreotide Implant in Patients With Acromegaly

NCT01295060 ·Status: TERMINATED ·Phase: PHASE3

A Single-dose Study of Octreotide Injection in Healthy Adult Subjects

NCT05761431 ·Status: COMPLETED ·Phase: PHASE1

Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly

NCT00225979 ·Status: COMPLETED ·Phase: PHASE3

Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly

NCT00376064 ·Status: COMPLETED ·Phase: PHASE4

Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly

NCT02685709 ·Status: COMPLETED ·Phase: PHASE3

Octreotide Efficacy and Safety in First-line Acromegalic Patients

NCT00171886 ·Status: COMPLETED ·Phase: PHASE4

A Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult Volunteers

NCT03571594 ·Status: TERMINATED ·Phase: PHASE1

Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly

NCT00372697 ·Status: COMPLETED ·Phase: PHASE3

Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic Patients

NCT00088582 ·Status: COMPLETED ·Phase: PHASE2

Ultrasound Guided Octreotide LAR Injection in Acromegaly

NCT00552071 ·Status: COMPLETED ·Phase: PHASE4

Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas

NCT00242541 ·Status: TERMINATED ·Phase: PHASE4

Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients

NCT00642421 ·Status: TERMINATED ·Phase: PHASE3

Efficacy and Safety of C2L-OCT-01 PR in Acromegalic Patients

NCT00616551 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly

NCT03252353 ·Status: UNKNOWN ·Phase: PHASE3

The Effect of Subcutaneous Infusions of 3 Doses of DG3173 on Growth Hormone Levels in Untreated Acromegalics

NCT02217800 ·Status: COMPLETED ·Phase: PHASE2

An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly

NCT01995734 ·Status: APPROVED_FOR_MARKETING

Preoperative Octreotide Treatment of Acromegaly

NCT00521300 ·Status: COMPLETED ·Phase: PHASE4

Acute Application of Pegvisomant and Octreotide in Acromegaly

NCT00595140 ·Status: COMPLETED ·Phase: PHASE4

Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)

NCT02299089 ·Status: COMPLETED ·Phase: PHASE2

Study of the Effect of Growth Hormone-Releasing Hormone Antagonist on Growth Hormone Release in Acromegaly

NCT00004332 ·Status: COMPLETED

Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly

NCT00461149 ·Status: COMPLETED ·Phase: PHASE4

Single Dose Pharmacology Study of DG3173 and Octreotide in Acromegalic Patients.

NCT02235987 ·Status: COMPLETED ·Phase: PHASE2

An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly

NCT00171730 ·Status: COMPLETED ·Phase: PHASE2

An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.

NCT01582061 ·Status: COMPLETED ·Phase: PHASE3

Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic Patients

NCT00128232 ·Status: COMPLETED ·Phase: PHASE3